Likewise, several proteins with different cell functions have been described to be potential targets for increasing lenvatinib effectiveness in human HCC, such as ADAMTS-like protein 5 (ADAMTSL5) [37], stomatin-like protein 2, mitochondrial (STOML2) [38] or fibroblast growth factor receptor 1 (FGFR1) [39]; but only STOML2 have shown to mediate the anti-migratory effects of lenvatinib [38], as we observed with NRP1. Here, ADAMTSL5 is linked to hepatocellular carcinoma.